about
A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer.Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trailNovel drugs targeting the androgen receptor pathway in prostate cancer.Antitumor activity in RAS-driven tumors by blocking AKT and MEK.First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.Neoadjuvant erlotinib and surgical resection of a stage iiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation.Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationAntitumor activity of nivolumab on hemodialysis after renal allograft rejection.Recent advances in second-line treatment of castration-resistant prostate cancer.Appraising iniparib, the PARP inhibitor that never was--what must we learn?Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits.Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review.AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies.Pharmacological risk factors for amphotericin B nephrotoxicity in children.Octreotide in bronchobiliary fistula management.Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study.Unscheduled return visits to the pediatric emergency department-one-year experienceChoroidal lymphoma with orbital and optic nerve extension: case and review of literatureImmune Checkpoint Inhibitors: Game Changing Cancer Therapy With a Cardiac Cost. What Are the Mechanisms and Unresolved Questions in Cardiotoxicity?
P50
Q30248333-66543029-2A31-40A6-A53E-724E92B5886CQ30251429-47FD28D3-8A94-407D-B77D-44EFDDF75DA3Q34113504-858D428B-6179-46EA-8179-633EFC10F07DQ34395777-D9C8DCA3-27C6-4948-8496-64AF9279778EQ35103514-6DD1ECB8-478A-4135-888B-F933BDA141D6Q35881827-F47E4349-4100-44B7-9FE6-213F0884F573Q36000269-398B15E0-68E8-4707-9E97-7F1DA72ABCAFQ36087929-373114EE-167C-4094-9DF5-C54A75C913BCQ37346073-28C191E0-202B-4A65-94AF-B96ADD4427F8Q37898500-D0022516-80B3-48B6-AEA7-F2BF205743C6Q38152942-CCD30689-3AC8-423F-BEDA-90A3F3F28A60Q38239754-0D2B26F3-F89F-47B9-9614-A9395AF7898CQ38372019-81E79707-2C88-433A-A4D3-CC61A74640AAQ38589647-FBAA7985-7CD4-4810-8984-091F52150CD6Q39013354-ED9A1CB4-6620-4ADC-8AF8-8583075C8324Q43599634-CB041ABB-06CF-4579-9636-D4C5268BA4C3Q45089659-A98F6C6C-B3A7-4895-B612-82E88EE9E402Q52643292-398CAF2B-19DA-4BEA-A486-274E1CFA0DF1Q80123761-2693B4E5-69DE-48EC-B80C-C71F77BA539CQ83446522-E7F0D7A8-679B-44F1-97B1-5E7BC6589B30Q89364710-9504C590-D6C0-4D48-848F-2F3C3F8DC654
P50
description
researcher ORCID ID = 0000-0002-0347-5541
@en
name
M Ong
@ast
M Ong
@en
M Ong
@es
M Ong
@nl
type
label
M Ong
@ast
M Ong
@en
M Ong
@es
M Ong
@nl
prefLabel
M Ong
@ast
M Ong
@en
M Ong
@es
M Ong
@nl
P1153
55877515900
P31
P496
0000-0002-0347-5541